<DOC>
	<DOCNO>NCT01428726</DOCNO>
	<brief_summary>The aim study assess efficacy safety NT-KO-003 treatment relapse remit multiple sclerosis , compare two dos versus placebo .</brief_summary>
	<brief_title>A Phase IIa Study NT-KO-003 Multiple Sclerosis</brief_title>
	<detailed_description>This Phase IIa study , double blind , placebo Controlled , Multicenter Study involve 99 patient relapse remit multiple sclerosis . After sign informed consent form , subject randomize three treatment arm : placebo , NT-KO-003 low dose NT-KO-003 high dose . Treatment continue daily 6 month . A MRI clinical evaluation perform monthly . Safety assess 6 month treatment 15 day finalization treatment . Patients allow continue arm study , blind way , study finalize optional extension treatment . Patient sign Extension Informed Consent MRI perform patient still treatment 12 month inclusion core study ( visit 0 ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Inclusion Criteria Patients meet diagnosis criterion MS accord guideline provide McDonald et al ( 1 ) Patients meet diagnosis criterion RRMS Patients clinical disability measure EDSS score 0 5.0 inclusive Patients present least 1 relapse previous 2 year presence least 1 gadoliniumenhanced lesion previous 1 year Patients age 18 55 year old , either gender Exclusion Criteria Patients candidate treatment drug modify course disease accord criterion Regulatory Agencies country , unless patient refuse initiate therapy decide postpone start therapy Patients relapse 30 day period baseline visit Patients treatment NTKO003 Medical condition hypotension , insulinoma , hyperuricemia Patients Diabetes define ADA criterion ( 2 ) Other condition : drug abuse , inability consent , inability perform procedures Clinical Trial Contraindications MRI study : claustrophobia , heart pacemaker condition would preclude proximity strong magnetic field Contraindications treatment NTKO003 excipients : allergy , hypersensitivity Patients know allergy contraindication administration intravenous gadoliniumbased agent ( chronic acute renal failure accord The Renal Association NICE guideline ( 3 ) ) Corticosteroid therapy last month Interferonbeta Glatiramer acetate therapy last 3 month Natalizumab therapy last 6 month Patients treat chemotherapy ( Mitoxantrone , Azathioprine , Cyclophosphamide , Cladribine , Methotrexate ) monoclonal antibody deplete population cell ( rituximab , alemtuzumab , ocrelizumab , daclizumab ) last 12 month enter previous trial treatment development last 3 month Patients participate another Clinical Trial moment screen visit Patient receive liver transplantation candidate liver transplantation Positive pregnancy test , breast feeding woman childbearing potential use highly effective method contraception Male patient follow adequate contraceptive measurement Fingolimod therapy last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>NT-KO-003</keyword>
	<keyword>RRMS</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>Phase IIa</keyword>
</DOC>